NUVB Nuvation Bio Inc.
FY2025 10-K
Nuvation Bio Inc. (NUVB) filed its fiscal year 2025 10-K annual report with the SEC on Mar 2, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Global oncology focused on developing novel small molecule therapies for difficult-to-treat cancers, leveraging medicinal chemistry and clinical data
- • New emphasis: U.S. commercial launch of IBTROZI (taletrectinib) for ROS1+ NSCLC approved June 2025, plus new Eisai partnership for European and other territories in 2026
Management Discussion & Analysis
- • Revenue and profitability data not disclosed in MD&A section
- • No segment performance details provided
Risk Factors
- • Regulatory risk: FDA approval and post-approval obligations for IBTROZI (taletrectinib) granted June 11, 2025 for ROS1+ NSCLC treatment
- • Geopolitical risk: Commercial partnerships in Japan (NK) and China (Innovent) expose revenue to MHLW and NMPA regulatory environments
Get deeper insights on Nuvation Bio Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.